Drugs in Context’s Post

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. https://ja.ma/3Uu8KAG

In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with high-risk biochemically recurrent prostate cancer following prostatectomy. https://ja.ma/3yPKwJl

A groundbreaking study has shown that bromelain significantly boosts the effectiveness of HIPEC in treating appendiceal cancer by aiding mucin dissolution. When used with NAC, bromelain enhances the cytotoxicity of HIPEC drugs, suggesting a potential revolution in managing peritoneal carcinomatosis. These findings could greatly influence future surgical protocols and patient outcomes. #Oncology #SurgicalInnovation #CancerResearch

The best neoadjuvant regimen for the treatment of patients with melanoma is still being investigated. Today, we reviewed JAMA Oncology most recent analysis on this.🤓 📍 Neoadjuvant therapy with dual check point inhibition was associated with higher pathologic complete response. 📍 Single agent was associated with less serious side effects compared to dual check point. 📍 However, 46% of patients who were treated with dual check point were unable to complete neoadjuvant treatment. The significance of this is that more randomized studies with a uniform population are needed to establish a treatment standard. #melanoma #melanomadoctor #oncologist #skincancerdoctor 🤓 https://lnkd.in/e6bAJX_F

🚨 Did You Miss Our Webinar? Now Watch It On-Demand! 🚨 If you were unable to attend our recent webinar, "How to Design a Successful 3D Tumor Model Co-Culture Study," don’t worry! You can now access the full recording at your convenience. Watch the webinar : https://hubs.li/Q02NTF7p0 Catch up on this informative session and enhance your oncology research with advanced ex vivo 3D tumor model co-culture methodologies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture

Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001. Great news and an excellent validation of Thermosome´s approach, Pascal Schweizer and team! Kerstin Pino Tossi, Frank Hermann, MD, Katrin Schmidthals #targetedcancertherapy #oncology #cancertherapy #thermosensitive #clinicaldata #softtissuesarcoma #doxorubicin #chemotherapy https://lnkd.in/e8k4kr9m

🚨Highlights from ESMO 2024! Prof Dr Mariana Brandao, medical oncologist at Institut Jules Bordet, shares key findings from metastatic NSCLC studies: - DEDICATION-1: Optimising pembrolizumab dosing for advanced NSCLC shows potential to reduce treatment costs without compromising efficacy. - REZILIENT1: Targeted therapy with zipalertinib shows promise in patients with EGFR exon 20 insertion mutations. - ABBV-400: A novel ADC targeting c-Met shows a 48% ORR but requires careful management due to significant toxicities. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #LungCancer #Oncology #CancerResearch #ClinicalTrials

At #ESMO24 I had the pleasure to Chair the mini-oral session on #NSCLC 🙏 All the presentations were very interesting, but I would highlight these promising and potentially practice-changing trials: - DEDICATION-1: Optimising pembrolizumab dosing for advanced NSCLC shows potential to reduce treatment costs without compromising efficacy. - REZILIENT1: Targeted therapy with zipalertinib shows promise in patients with EGFR exon 20 insertion mutations. - ABBV-400: A novel ADC targeting c-Met shows a 48% ORR but requires careful management due to significant toxicities MediMix Institut Jules Bordet #clinicalresearch #oncology #lungcancer

Patient-derived xenograft organoids- Tumirgraft3D models to study Immuno-oncology study- with Champions CO-CULTURE models - design your preclinical study with the most clinically relevant models - that mimics clinical populations (including pre-treatments and high level -ionic characterizations). Listen to the webinar and start your new study today. #pdx #exvivo #tumorpdx #pdxo #IO #coculture #cart #TILs #immunecheckpointinhibitors

Discover the latest insights on first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). This comprehensive network meta-analysis (NMA) compares the effectiveness of various therapies, highlighting the benefits of talazoparib plus enzalutamide. 📊 Key Findings: • Talazoparib plus enzalutamide shows significant therapeutic benefits. • NMAs are crucial for guiding treatment decisions in mCRPC. Kudos to EVERSANA authors: Imtiaz Samjoo, Jenna Ellis, Samantha Craigie, and Anja Haltner. Read more: https://ow.ly/Ma6S50U0Xp6 #ProstateCancer #Oncology #NetworkMetaAnalysis #NMA